Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial-Reference-Cited by-同舟云学术

Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial

Published:2015-11 Issue:10008 Volume:386 Page:2059-2068
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Williams Bryan,MacDonald Thomas M,Morant Steve,Webb David J,Sever Peter,McInnes Gordon,Ford Ian,Cruickshank J Kennedy,Caulfield Mark J,Salsbury Jackie,Mackenzie Isla,Padmanabhan Sandosh,Brown Morris J

Publisher

Elsevier BV

Subject

General Medicine

Reference21 articles.

1. Resistant hypertension;Myat;BMJ,2012

2. Resistant hypertension: an unmet treatment need;Williams;Lancet,2009

3. Systematic review and meta-analysis of the prevalence of resistant hypertension in treated hypertensive populations;Achelrod;Am J Hypertens,2015

4. 2013 ESH/ESC Guidelines for the management of arterial hypertension

5. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research;Calhoun;Hypertension,2008

Cited by 944 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. deliVERy of optimal blood pressure coNtrol in afrICA (VERONICA)-Nigeria study: Rationale and design of a randomized clinical trial;American Heart Journal;2024-11

2. Options for patients with out-of-control blood pressure: after all avenues have been exhausted;Expert Review of Cardiovascular Therapy;2024-09-11

3. Prevalence, Clinical Characteristics, and Treatment of Patients with Resistant Hypertension: A Single-Center Study;Journal of Cardiovascular Development and Disease;2024-09-05

4. Pressing Update: Aprocitentan for the Treatment of Hypertension;Annals of Pharmacotherapy;2024-09-04

5. Advances in Primordial, Primary, and Secondary Prevention of Stroke in Diverse Populations;Stroke;2024-09